Novo Nordisk A/S (NYSE:NVO) Holdings Boosted by Addison Advisors LLC

Addison Advisors LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 12.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,331 shares of the company’s stock after acquiring an additional 255 shares during the period. Addison Advisors LLC’s holdings in Novo Nordisk A/S were worth $241,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Headlands Technologies LLC raised its holdings in shares of Novo Nordisk A/S by 33.1% during the fourth quarter. Headlands Technologies LLC now owns 2,857 shares of the company’s stock valued at $296,000 after buying an additional 711 shares during the last quarter. Citizens Financial Group Inc. RI raised its holdings in shares of Novo Nordisk A/S by 1.8% during the fourth quarter. Citizens Financial Group Inc. RI now owns 13,703 shares of the company’s stock valued at $1,418,000 after buying an additional 239 shares during the last quarter. Truist Financial Corp raised its holdings in shares of Novo Nordisk A/S by 1.6% during the fourth quarter. Truist Financial Corp now owns 597,059 shares of the company’s stock valued at $61,766,000 after buying an additional 9,450 shares during the last quarter. Callan Capital LLC raised its holdings in shares of Novo Nordisk A/S by 260.8% during the fourth quarter. Callan Capital LLC now owns 21,259 shares of the company’s stock valued at $2,199,000 after buying an additional 15,366 shares during the last quarter. Finally, Herold Advisors Inc. raised its holdings in shares of Novo Nordisk A/S by 108.3% during the fourth quarter. Herold Advisors Inc. now owns 5,000 shares of the company’s stock valued at $517,000 after buying an additional 2,600 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock traded up $1.06 during mid-day trading on Friday, hitting $126.85. The company’s stock had a trading volume of 3,312,457 shares, compared to its average volume of 3,307,405. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $569.24 billion, a P/E ratio of 46.90, a P/E/G ratio of 2.10 and a beta of 0.41. Novo Nordisk A/S has a twelve month low of $75.56 and a twelve month high of $138.28. The stock’s fifty day moving average price is $126.86 and its two-hundred day moving average price is $111.98.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.05. The firm had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. Research analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were paid a $0.664 dividend. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend was Friday, March 22nd. This represents a yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 49.17%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on NVO. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective on the stock. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective on the stock. Finally, UBS Group started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating on the stock. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.